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INTRODUCTION
The Hedgehog (Hh) signaling pathway, also known as 
Hedgehog-Patched (Hh-Ptch), Hedgehog-Gli (Hh-Gli) or 
Hedgehog-Patched-Smoothened (Hh-Ptch-Smo), is an evolu-
tionarily conserved pathway of signal transmission from the 
cell membrane to the nucleus. The Hh signaling pathway plays 
a significant role in the normal embryonic development of 
invertebrates and vertebrates [1]. The Hh gene is also relevant 
for proper segregation, i.e. the polarity of the organism and the 
development of many tissues and organs.
The Hh pathway is mostly inactive or poorly active in the 
adult organism. If necessary, it can be activated, for example, 
in wound healing [2]. Furthermore, the pathway is involved 
in the maintenance of somatic stem cells and pluripotent 
cells important for tissue repair [3], such as mammary  [4], 
skin [5], neural [6], erythropoietic [7], and lung stem 
cells [8], as well as some epithelial cells of internal organs [9]. 
Accordingly, Hh signaling is critical for regeneration of the 
lung epithelium [8], prostate epithelium [10], and exocrine 
pancreas cells [11].
In other tissues, the Hh signaling pathway is present only 
in primary cilia (PC), organelles that consist of microtubules 
and emanate from the cell surface, receiving mechanical, 
chemical, and thermal signals [12]. All components of the Hh 
signal transduction pathway are found in the PC [13].
Some studies indicate that Hh signaling can be involved in 
various stages of carcinogenesis in different tumors. For exam-
ple, in pancreatic and esophageal cancer, the activation of this 
signaling pathway is found in the early stages of tumor as well 
as in metastatic tumors [14,15]. In other tumors, such as gastric 
cancer and prostate cancer, the activation of the Hh signaling 
pathway is associated with tissue invasion and increased met-
astatic potential. In accordance with those findings, the inhibi-
tion of the Hh signaling pathway reduces tumor cell prolifera-
tion in prostate and gastric cancer [10,16].
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ABSTRACT
The Hedgehog (Hh) signaling pathway was first identified in the common fruit fly. It is a highly conserved evolutionary pathway of signal trans-
mission from the cell membrane to the nucleus. The Hh signaling pathway plays an important role in the embryonic development. It exerts its 
biological effects through a signaling cascade that culminates in a change of balance between activator and repressor forms of glioma-associated 
oncogene (Gli) transcription factors. The components of the Hh signaling pathway involved in the signaling transfer to the Gli transcription 
factors include Hedgehog ligands (Sonic Hh [SHh], Indian Hh [IHh], and Desert Hh [DHh]), Patched receptor (Ptch1, Ptch2), Smoothened 
receptor (Smo), Suppressor of fused homolog (Sufu), kinesin protein Kif7, protein kinase A (PKA), and cyclic adenosine monophosphate 
(cAMP). The activator form of Gli travels to the nucleus and stimulates the transcription of the target genes by binding to their promoters. The 
main target genes of the Hh signaling pathway are PTCH1, PTCH2, and GLI1. Deregulation of the Hh signaling pathway is associated with devel-
opmental anomalies and cancer, including Gorlin syndrome, and sporadic cancers, such as basal cell carcinoma, medulloblastoma, pancreatic, 
breast, colon, ovarian, and small-cell lung carcinomas. The aberrant activation of the Hh signaling pathway is caused by mutations in the related 
genes (ligand-independent signaling) or by the excessive expression of the Hh signaling molecules (ligand-dependent signaling – autocrine or 
paracrine). Several Hh signaling pathway inhibitors, such as vismodegib and sonidegib, have been developed for cancer treatment. These drugs 
are regarded as promising cancer therapies, especially for patients with refractory/advanced cancers.
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HH SIGNALING PATHWAY
Three proteins are involved in Hh signaling activation: 
Hedgehog (Hh) ligand, Patched (Ptch) and Smoothened 
(Smo) [17].
In the absence of Hh ligand, Ptch localizes to the base of 
the PC and represses the activity of Smo by inhibiting its trans-
location into the PC [18]. This leads to proteolytic cleavage of 
full-length glioma-associated oncogene (GliFL) to Gli repres-
sor (GliR) after phosphorylation by protein kinase A (PKA), 
glycogen synthase kinase-3 (GSK3), and casein kinase 1 
(CK1) [19]. GliR binds to Hh target gene promoters and keeps 
Hh target genes switched off (Figure 1A) [20].
The Hh signaling cascade is activated by Hh binding to 
Ptch1 protein. The Hh-Ptch complex is internalized, and both 
proteins are degraded in lysosomes [21]. The binding relieves 
the Smo inhibition, and the Hh signal is now able to be trans-
mitted downstream of Smo via cytoplasmic protein complex 
composed of kinesin protein (Kif7), Suppressor of fused (Sufu), 
and GliFL. Smo travels to the tip of the PC and signals Sufu to 
release Gli activator (GliA). GliA then migrates to the nucleus 
and activates the expression of the target genes (Figure 1B) [22]. 
This pathway of signal transduction, where Hh regulates the 
Gli family of transcription factors, is called the canonical Hh 
signaling pathway. In the non-canonical Hh signaling pathway, 
Hh proteins signal through Gli-independent mechanisms.
ELEMENTS OF HH SIGNAL 
TRANSDUCTION
Hh gene/protein
The Hh gene is highly conserved from fruit flies to 
humans, and is a key regulator in embryonic development 
[1]. Unlike Drosophila melanogaster (D. melanogaster), where 
one Hh gene has been identified, in vertebrates, three Hh 
gene family members have been detected: the Sonic Hedgehog 
(SHh), Indian Hedgehog (IHh), and Desert Hedgehog (DHh) 
gene [23-25]. The products of any of these three genes can bind 
to Ptch1 receptor and activate the Hh signaling pathway [26], 
but they perform this activity in various organ systems [23,25]. 
Hh proteins can act as mitogens, morphogens, and differen-
tiation factors at longer or shorter distances, during different 
stages of development and in different tissues [17].
The most studied Hh ligand is SHh. It has the highest 
activity and is involved in the development of various organs 
during embryogenesis. SHh is expressed in the central nervous 
system, lungs, teeth, intestines, and hair follicles during devel-
opment [27-30]. SHh signaling can be autocrine (binds to the 
same cell from which it is excreted) or paracrine (binds to the 
nearby cells or induces changes in cells at longer distances).
IHh is involved in endochondral bone formation, as a neg-
ative regulator of chondrocyte differentiation [31], and par-
ticipates in the development of gastrointestinal tract [32] and 
mammary glands [4].
Of all discovered Hh proteins, DHh is the closest homo-
logue of D. melanogaster Hh ligand [33]. Its expression is 
largely restricted to gonads, including Sertoli cells in the testis, 
where it plays a key role in the differentiation of germ cells [34].
All Hh proteins undergo maturation before the active 
ligand is generated and released from the cell and before the 
activation of Hh signaling pathway [35]. After the translation, 
N-terminal signal sequence is removed from a ~45 kDa long 
polypeptide, which is then autocatalytically cleaved between 
glycine and cysteine to form an N-terminal fragment. The 
C-terminal domain (autoprocessing domain) of the Hh 
polypeptide promotes the binding of cholesterol to glycine 
FIGURE 1. A simplified display of the Hedgehog signaling pathway. (A) In the absence of Hedgehog ligand, full-length Gli is phos-
phorylated by protein kinase A, glycogen synthase kinase-3, and casein kinase 1. This leads to proteolytic cleavage of the full-length Gli 
into Gli repressor. Gli repressor represses the expression of target genes, (B) after binding of Hedgehog ligand, Smoothened protein is 
phosphorylated by protein kinase A and casein kinase 1. The inhibitory effect of Sufu is removed and Gli activator is formed. Gli activator 
induces the transcription of target genes. Red symbols represent the inhibitory effect, and green arrows show the activating effect. 
Hh - Hedgehog; Ptch - Patched; Smo - Smoothened; Gli - glioma-associated oncogene; GliFL - full-length Gli; GliA - Gli activator; GliR - Gli 
repressor; CK1 - casein kinase 1; PKA - protein kinase A; GSK3 - glycogen synthase kinase-3.
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at the C-terminus of N-terminal fragment, after which a 
~19 kDa N-terminal Hh signaling domain (HhN), associated 
with a number of known signaling activities, is formed [36]. 
Subsequently, a palmitic acid moiety is added to the cyste-
ine on the N-terminus of Hh by the acyltransferase Skinny 
Hedgehog (Ski), resulting in the formation of dually modified 
Hh signaling domain (HhNp), i.e., active Hh protein [37]. The 
secretion of mature, functionally active Hh proteins is regu-
lated by Dispatched (Disp) protein, which allows their release 
from the cells.
Ptch gene/protein
Ptch is the receptor for Hh protein. Two Ptch homologs 
have been isolated in vertebrates: Ptch1 and Ptch2 [38]. SHh, 
IHh, and DHh ligands bind with similar affinity to both of 
them, and both proteins may repress the activity of Smo pro-
tein [39]. The human Ptch1 gene is located on chromosome 
9q22.3; it contains 23 exons and encodes a glycoprotein of 1447 
amino acids [40,41]. The Ptch2 gene is located on 1p34.1 and 
encodes a 1203-amino acid protein. Ptch1 and Ptch2 genes have 
different functions based on their different expression during 
epidermal development [42]. The Ptch1 is primarily expressed 
in mesenchymal cells that produce SHh proteins, while the 
Ptch2 is expressed in skin and testicular epithelial cells [43].
Ptch1 protein is a 12-pass transmembrane protein with two 
large extracellular loops and two large intracellular loops [25]. 
Within the extracellular loop structure, there is a sterol-sens-
ing domain (SSD) that is thought to interact with cholesterol 
bound to Hh protein [44]. In the absence of Hh, Ptch blocks 
the pathway activity [45]. However, when Hh ligand binds to 
Ptch, Hh relieves the inhibition of Ptch to activate the signal 
transduction [46]. Subsequently, there is no Smo blockade 
anymore, which results in the modulation of Gli transcrip-
tion factors. Ptch also sequesters Hh ligand and restricts the 
range of signaling of the free ligand [47]. In cells where Ptch is 
absent, Hh protein is further dispersed [48] and it induces the 
targeted gene expression at longer distances [49]. The mecha-
nism by which Ptch regulates Smo is still not understood, but 
it has been shown that Hh binding causes the internalization 
of Ptch from the cell surface and promotes the accumulation 
of Smo at the cell surface [18].
Ptch and Hh proteins regulate the cell cycle in two ways [50]. 
First, Ptch without Hh ligand binds maturation promoting fac-
tor (MPF), which is composed of cyclin B1 and cyclin-depen-
dent kinase 1 (CDK1). Binding or retaining MPF in the cyto-
plasm, prevents its activity. When Hh binds to Ptch, cyclin B1 is 
released and the cell cycle continues [17]. Second, the Hh signal 
transmission pathway leads to the transcription of cyclin D and 
cyclin E, which also promotes the cell cycle progression [51].
Several observations suggest that, besides Ptch1, other 
receptors bind Hh ligands and participate in the Hh signaling 
pathway activation [52,53]. Negative receptor of Hh signaling 
is Hedgehog-interacting protein (Hhip) [54], while Cdo and 
Boc bind vertebrate Hh proteins and positively regulate Hh 
signaling. It is not yet fully known if they synergize or compete 
with Ptch1 for binding to Hh [55]. Some evidence has shown 
that the membrane protein growth arrest-specific 1 (GAS1), 
known as a negative regulator of Hh signaling, also modu-
lates Hh signaling positively [56]. These negative and positive 
receptors most likely play a key role in monitoring the magni-
tude and range of Hh signaling pathway [57].
Smo gene/protein
As previously mentioned, Smo protein is a co-recep-
tor in the Hh signaling pathway, i.e.  it represents a signaling 
component of the receptor complex. It is a seven-pass trans-
membrane protein, structurally similar to G-protein-coupled 
receptors [58], and has an extracellular cysteine-rich domain 
(CRD) that is indispensable for its function [59].
Smo is considered to be a positive Hh signaling pathway 
regulator because it is constitutively active in the absence 
of inhibitory Ptch1, and it promotes the activation of down-
stream components of this signaling pathway [60].
The mechanism by which Ptch1 inhibits Smo is still not 
clear. The suggested mechanism [61] based on the physi-
cal interaction between Smo and Ptch1, in which they form 
a membrane-associated receptor complex, has not been 
confirmed in vivo [47]. Ptch1 possibly functions through 
the changes in the distribution or concentration of a small 
molecule that affects Smo [62]. Ciliary localization of Ptch1, 
enabled by the ciliary localization sequence (CLS) within its 
carboxyl-terminal tail, has one of the main roles in the inhibi-
tion of Smo. CLS also unlocks Ptch1 transport into the PC [63]. 
Oxysterols [64] and Vitamin D3 derivatives [65] may func-
tion as endogenous regulators of Smo activity. Despite these 
insights on the regulators of Smo activity, the mechanisms by 
which Ptch1 represses Smo and how Hh ligand counters this 
effect remain unknown.
After the binding of Hh ligand and degradation of Ptch1 
protein, Smo is phosphorylated by PKA and CK1, and its 
endocytosis and degradation are blocked [66]. Smo transmits 
a signal to the cytoplasm in a phosphorylation cascade, where 
Gli protein is the final target (Figure 1B).
Gli gene/protein
Gli family consists of zinc finger proteins, and is named 
after glioblastoma from which they were initially isolated [67].
In vertebrates, there are three members of Gli gene fam-
ily: Gli1, Gli2, and Gli3 [68]. GLI1 protein acts as a transcrip-
tional activator [69]. Hh ligands induce the expression of Gli1, 
which also provides a positive feedback for Hh signaling [70]. 
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The activator domain of GLI1 consists of 18 amino acids, and 
it probably forms a negatively charged helix that is similar to 
viral protein 16 [71]. GLI2 primarily functions as a transcrip-
tional activator, while GLI3 mainly functions as a repressor in 
Hh signaling [72].
Gli proteins regulate the expression of target genes by 
directly binding to their promoters [73]. GLI1 and GLI3 pro-
teins recognize the 5’-GACCACCCA-3’ sequence in target 
gene promoters [74], and GLI2 recognizes almost the identical 
5’-GAACCACCCA-3’ motive [75].
In the absence of Hh ligand, GliFL is phosphorylated by 
PKA, GSK3 and CK1, and recognized by β-transducin-repeat 
containing protein (β-TrCP). This leads to proteolytic cleavage 
of GliFL into C-terminally truncated repressor form, GliR [76]. 
GliR translocates to the nucleus where it binds to Hh target 
gene promoters and represses their expression (Figure  1A). 
The binding of Hh ligand leads to the release of Gli from Sufu 
and the formation of GliA [77]. GliA then translocates to the 
nucleus, binds to target gene promoters, and activates the 
transcription of Hh target genes (Figure 1B).
The activation of canonical Hh signaling results in the sup-
pression of proteolytic degradation of Gli proteins, thereby 
increasing their cytoplasmic and nuclear levels, and hence, 
the transcription of target genes in the Hh signaling pathway. 
Studies have shown that the expression of Gli transcription 
factors and their activation is also regulated by other signal-
ing pathways. For example, in esophageal carcinoma, the 
mammalian target of rapamycin (mTOR)/ribosomal pro-
tein S6 kinase beta-1(S6K1) signaling pathway activates GLI1 
by phosphorylation, leading to the release of GLI1 from the 
Sufu protein complex and its translocation into the nucleus 
[78]. In addition, it has been reported that the transforming 
growth factor beta (TGF-β), epidermal growth factor recep-
tor (EGFR), mitogen-activated protein kinases (MAPK), and 
fibroblast growth factor (FGF) signaling pathways can also 
induce the expression of Gli transcription factors [79].
Suppressed fusion protein (Sufu)
Sufu is a crucial negative regulator of the Hh pathway, 
and it functions between Smo and Gli transcription factors. It 
binds directly to Gli proteins [80]. In a stimulated Hh signaling 
pathway, active Smo leads to the recruitment of Sufu-Gli to 
cilia, followed by a rapid dissociation of the complex and ini-
tiation of target gene transcription [81]. Sufu inhibits Gli pro-
teins by preventing their translocation into the nucleus [82]. It 
plays a key role in the stabilization and processing of Gli and 
thus maintains accurate Hh signaling [77]. Sufu also localizes 
to the nucleus where it can bind to Gli-binding sequences in 
DNA molecule and prevent gene transcription [83].
Kif7
The kinesin protein Kif7 is a component of Hh signaling 
that can act as both a positive and negative regulator [84]. In 
response to Hh activation, Kif7 localizes to the tip of the PC, 
and it can control the cilium structure and organize a special-
ized compartment necessary for Hh signaling [85]. When Hh 
signaling is induced, Gli proteins also translocate to the PC 
tip [86]. The mechanisms of Kif7 positive and negative roles 
are not completely understood. One possible mechanism is 
the post-translational control of Kif7 phosphorylation by pro-
tein phosphatase 2A (PP2A) [87].
Cyclic AMP (cAMP)-dependent PKA
cAMP-dependent PKA is also an important negative 
regulator of the Hh pathway (Figure 1) [88]. It is localized at 
the base of cilia and regulates the formation of GliR/GliA 
complex [89]. PKA activity is crucial for Hh signaling. In the 
TABLE 1. Hh signaling pathway target genes
Gene Full name of protein Effect of the gene product References
Ptch1 Patched 1 Indicator of the activated signaling pathway, negative feedback [93]
Ptch2 Patched 2 Indicator of the activated signaling pathway [93]
Gli1 Glioma-associated oncogene 1 Indicator of the activated signaling pathway, positive feedback [93]
Hhip Hedgehog-interacting protein Hh signaling pathway regulation [54]
CCND2 G1/S-specific cyclin-D2 Cell cycle regulator [51]
CCNE1 G1/S-specific cyclin-E1 Cell cycle regulator [51]
MYCN N-myc proto-oncogene protein Cell proliferation and tumorigenesis [95]
BCL2 B-cell lymphoma 2 Apoptosis regulator [94]
ABCG2 ATP-binding cassette subfamily G member 2 Transport of many positive and negatively charged hydrophobic molecules [96]
FGF4 Fibroblast growth factor 4
Mitogenic activity, involved in various biological 
processes (embryonic development, morphogenesis, and 
tissue repair)
[97]
VEGFA Vascular endothelial growth factor A Angiogenesis, vasculogenesis, endothelial cell growth [98]
PAX6, PAX7, PAX9 Paired box protein Pax-6, 7 and 9 Transcription factors during embryogenesis [99]
JAG1 Jagged 1 Notch ligand and Wnt signaling pathway [101]
FOXM1 Forkhead box protein M1 Transcription factor [100]
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absence of Hh ligand, PKA phosphorylates Gli proteins, which 
are then cleaved to the repressor form of GliR and repress Hh 
target gene expression (Figure 1A) [90]. PKA may also inhibit 
Gli proteins by modulating their interaction with Sufu. One 
explanation as to how PKA inhibits Hh signaling is by block-
ing the localization of Sufu-Gli complex to cilia and inhibiting 
the Sufu-Gli dissociation [81]. The basal level of PKA activity 
maintains the suppression of Hh signaling pathway in the 
absence of Hh ligand. If the PKA activity is reduced, it causes 
ectopic expression of Hh target genes [91].
Target genes
The main target genes of Hh signaling pathway (Table 1) 
include the Ptch1, Ptch2, and Gli1 genes; their activation results 
in elevated levels of the respective mRNAs and proteins [92]. 
Increased expression of the Ptch1, Ptch2, and Gli1 genes is a 
highly reliable indicator of activated signaling pathway and 
provides negative (Ptch1) and positive (Gli1) regulation of Hh 
signaling with negative and positive feedback loop mecha-
nisms [93].
FIGURE 2. Three basic mechanisms of aberrant activation of Hedgehog signaling. (A) Type I - Ligand-independent Hedgehog signaling. 
This type includes: Ptch1 inactivating mutation (green asterisk) or Smo activating mutation (red asterisk), thereby Smoothened receptor 
can no longer be inhibited by Patched 1. The result is a constitutive activation of Hedgehog pathway in the absence of the ligand. (B) 
Type II - Ligand-dependent autocrine/juxtacrine Hedgehog signaling. The Hedgehog ligand is secreted by the tumor cell and taken up 
into the same tumor cell (autocrine manner) or into the nearby tumor cells (juxtacrine manner), thus activating the signal cascade down-
stream of the Hedgehog signaling pathway. (C-1) Type IIIa - Ligand-dependent paracrine signaling. The Hedgehog ligand is secreted 
by tumor cells and taken up by the stromal cells. Activated stromal cells synthesize and secrete signals, such as vascular endothelial 
growth factor and insulin-like growth factor, which are then taken back into the tumor cells to support their survival and growth. (C-2) 
Type IIIb - Ligand-dependent reverse paracrine signaling. The Hedgehog ligand is directly secreted by stromal cells and taken up by 
the tumor cells. Thus, the ligand helps the tumor cell proliferation and growth. Hh - Hedgehog; Ptch1 - Patched 1; Smo - Smoothened; 
Gli1 - glioma-associated oncogene 1; VEGF - vascular endothelial growth factor; IGF - insulin-like growth factor.
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Other target genes include Hedgehog-interacting pro-
tein (Hhip) [54], cell cycle regulators (CCND2 and CCNE1) 
[51], apoptosis regulator (BCL2) [94], MYCN [95], ABCG2 
[96], FGF4 [97], VEGFA [98], PAX6, PAX7, PAX9 [99], 
FOXM1 [100], JAG1, and members of the Wnt signaling path-
way [101]. Recent studies show the existence of an interaction 
between the Wnt and Hh signaling pathways [32,102].
Activation and deactivation of these Hh genes may con-
tribute not only to the development of normal tissues and 
organs, but also to tumorigenesis.
THE ROLE OF THE HH SIGNALING 
PATHWAY IN CANCER
Dysfunction or aberrant activation of the Hh signaling 
pathway is associated with developmental deformities and 
cancers [103], such as basal cell nevus syndrome (BCNS), also 
known as Gorlin syndrome, sporadic basal cell carcinoma 
(BCC), medulloblastomas (MBs), rhabdomyosarcomas, 
meningiomas [104], and others. According to the latest esti-
mates, the Hh signaling pathway contributes to the develop-
ment of one-third of all malignant tumors [60]. Deregulation 
of any component within the Hh pathway leads to its aberrant 
activation, resulting in malignant transformation. There are 
three proposed mechanisms of aberrant Hh signaling activa-
tion in different cancer types [22]. These are as follows:
•	 Type I - autonomous	and	ligand-independent	type	of	Hh	
signaling (Figure 2A);
•	 Type  II  -  ligand-dependent	 oncogenic	 Hh	 signaling	 in	
autocrine/juxtacrine manner (Figure 2B);
•	 Type IIIa/b - ligand-dependent	Hh	signaling	in	paracrine	
or reverse paracrine manner (Figure 2C).
Type I - ligand-independent signaling
The ligand-independent activation of Hh signaling in 
Type I is caused either by the activating mutations in the Smo 
or inactivating mutations in the Ptch1 or Sufu (Hh signaling 
negative regulators) leading to constitutive activation of Hh 
signaling in the absence of the ligand (Figure 2A) [105]. This 
link was first found in patients with a rare autosomal domi-
nant disorder, i.e.,  BCNS (Gorlin syndrome), where a Ptch1 
mutation on chromosome 9 was found [106]. These patients 
are at high risk for the development of BCCs and have an 
increased risk of developing other tumors, especially MBs, 
meningiomas, and rhabdomyosarcomas [104].
Somatic mutations of these genes have also been found 
in sporadic BCCs and MBs [107]. Sporadic BBC is the most 
common cancer in humans, and almost all cases are caused 
by a gene mutation leading to a constitutive activation of Hh 
signaling pathway.
The confirmation of these findings was found in many 
preclinical and clinical models. For example, an inactivat-
ing mutation in the Ptch1 was found in about 85% of spo-
radic BCCs  [106]. These observations have been supported 
by the fact that in Ptch1 heterozygous mice the formation 
of UV-induced BCC was more frequently observed [108]. 
Activating Smo mutations that reduce its inhibition by Ptch1 
have been found in 10% of sporadic BCCs. Rare mutations 
of the Sufu gene (<10% somatic) have also been found [105]. 
However, although the Sufu is a tumor suppressor gene, its 
targeted inactivation in mouse skin does not result in BCC 
development, suggesting that the Sufu heterozygosity is not 
sufficient for tumorigenesis  [109]. Furthermore, it has been 
found that the hyperactivation of Hh signaling after Gli over-
expression and activation of atypical protein kinase C (aPK-
C)-ι/λ (GLI1-positive regulator) can promote BCC devel-
opment regardless of the upstream components [107]. Gli2 
gene amplification is seen in 8% of BCCs, suggesting that the 
increase in the number of Gli2 copies can induce tumorigen-
esis as well [110]. In 30% cases of BCC, no mutations in Hh 
signaling pathway genes can be found [39]. Given all the above 
results, it can be concluded that, in most instances, BCC is a 
disease related to the aberrant activation of Hh signaling path-
way that leads to tumor cell proliferation and survival.
MB is a rare, aggressive tumor, predominantly present 
in children, and is another malignancy that occurs in 5% of 
patients with Gorlin syndrome [111]. The Hh signaling path-
way plays an important role in the embryonic development 
of the cerebellum, and consequently, its role in the formation 
of MB is not surprising. Purkinje cells release SHh, which 
induces mass proliferation of granule neuron progenitor 
(GNP) cells and delays neural differentiation. After early 
postnatal development, Hh signaling is normally downreg-
ulated in the brain. The formation of MB occurs when the 
Hh pathway is constitutively activated in GNP cells and the 
proliferation continues outside the normal developmen-
tal period [112]. More than one-third of sporadic MB cases 
are associated with aberrant activation of Hh pathway that 
is either linked to Ptch1 mutation or Ptch1 locus chromo-
somal loss (45% of cases) [113]. Somatic inactivating Smo or 
Sufu mutations each occur in about 14% of cases. While Smo 
mutations are more frequent in adults, mutations of Sufu 
are mostly found in pediatric patients (0–3  years) [114]. In 
preclinical animal models, Ptch1+/-  heterozygous mice and 
Sufu+/- heterozygous mice, deficient also in p53 alleles, both 
develop MBs [112].
In both BCCs and MBs, dysregulation of PKA and gua-
nine nucleotide-binding protein (GNAS), was also found. 
PKA is the main negative regulator of the Hh pathway, while 
G-protein alpha subunit, encoded by the GNAS gene, pro-
motes PKA-dependent cAMP activity. Therefore, it is not 
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surprising that reduced PKA activity triggers oncogenic Hh 
signaling and formation of MBs and BCCs. Furthermore, 
GNAS gene mutations have been found in human MBs [110] 
and in lesions similar to BCC [115], confirming their important 
role in Hh signaling. Ptch2 mutations, although rare, can be 
found in MBs and in BCCs as well [42].
Ptch1 gene mutations were detected in trichoepithelio-
mas  [116], esophageal carcinomas [117], and bladder carci-
nomas [118], whereas mutations of Ptch1 and Sufu have been 
found in a rare muscle tumor, rhabdomyosarcoma [119].
Type II - ligand-dependent autocrine/juxtacrine 
signaling
Type  II is ligand-dependent and responds to Hh in an 
autocrine/juxtacrine manner leading to tumor formation 
and growth (Figure  2B). Since the Hh pathway is activated 
in a cell-autonomous manner, Hh ligand is produced by and 
taken up by the same or surrounding tumor cells. The over-
expression of the ligand-dependent autocrine/juxtacrine Hh 
signaling pathway has been found in various tumors including 
stomach, esophageal, pancreatic [120], colorectal [121], ovar-
ian and endometrial [122], breast [123], prostate [16], lung [8], 
melanomas [124], gliomas [125], and other extracutaneous 
tumors. Apart from the Hh ligand overexpression, most of 
these tumors show ectopic expression of Ptch1 and Gli.
Studies of the activation of Hh signaling pathway in col-
orectal carcinomas (CRCs) are contradictory. A  few stud-
ies [126,127] found an increased level of the Hh pathway com-
ponents in CRC. In addition, in CRC cells in vivo, increased 
SHh expression was detected at both, the mRNA and protein 
level. These findings suggest that SHh is required for the devel-
opment of CRC. In contrast, other reports [120,128,129] claim 
that the Hh signaling pathway is inactivated during the CRC 
progression.
Type III - ligand-dependent paracrine signaling
Type III is ligand-dependent and uses paracrine signaling. 
Although paracrine Hh signaling plays an important role during 
normal embryonic development and is required for the growth 
and maintenance of many tissues [130], paracrine activation 
of Hh pathway in stromal cells has also been associated with 
various cancers, such as those of prostate, pancreas, and colon. 
Namely, Hh ligands, secreted by tumor cells, bind to Ptch1 
receptors on tumor stromal cells, which then undergo Hh path-
way activation. In a feedback loop, the stromal cells transmit 
the growth signals (vascular endothelial growth factor [VEGF], 
insulin-like growth factor [IGF], Wnt, PDGF, and BMP) to 
tumor cells, supporting and promoting their proliferation and 
differentiation (Figure  2C-1) [131]. In addition, Fan et al. [132] 
suggested that some prostate cancer cells signal to stromal cells 
in ligand-dependent and paracrine manner, and Theunissen 
and Sauvage [133] recently supported this finding. This suggests 
that, while some Hh ligand-expressing epithelial cancer cells do 
not respond to the ligands themselves, there is an activation of 
Hh signaling pathway in their surrounding stromal cells.
The “reverse” paracrine signal model has also been recog-
nized, but only in hematological malignancies such as B-cell 
lymphomas, multiple myelomas, and leukemias. In this model, 
tumors receive Hh ligand secreted directly from bone marrow 
or lymph node stromal cells. Thus, in the reverse paracrine 
ligand-dependent cancers, stromal cells provide a microenvi-
ronment that is favorable for tumor growth (Figure 2C-2). For 
that reason, surrounding stromal cells can also be considered 
as a therapeutic target [133].
Cancer stem cells (CSCs)
Recently, CSCs have emerged as an important factor in 
both tumor initiation and progression [134,135]. Within each 
tumor, there is a set of cells that act as stem cells: they divide 
slowly but, if necessary, they can very quickly proliferate and 
create a new population of tumor cells [136]. Activated sig-
naling pathways, including Hh, are involved in their growth, 
survival, migration, and proliferation [137]. Tumor stem 
cells have already been detected, for example, in multiple 
myeloma [137], pancreatic adenocarcinoma [138], breast can-
cer [139], and chronic myelogenous leukemia (CML) [140]. 
Due to their slow growth, CSCs are potentially resistant to 
conventional chemotherapy and radiotherapy, and they are 
thought to be the major cause of tumor relapse after such 
therapies. Therefore, new generations of antitumor drugs are 
being designed in an attempt to target signaling pathways, 
including Hh, specifically in CSCs [141].
Epigenetic changes
Recent studies show that, apart from mutations, the Hh 
signaling pathway can be disrupted by epigenetic changes, 
or more accurately, by methylation of gene promoters. So far, 
the methylation of the promoter of the Ptch1 gene has been 
described in dermoid cysts and ovarian fibromas [142] and 
in breast cancer [143], whereas in MBs, SHh ligand induces a 
local switch of epigenetic cofactors that cooperate with Gli in 
controlling the transcription outcomes [144].
CLINICAL AND THERAPEUTIC 
IMPLICATIONS
Recent findings in the Hh signaling pathway and its role 
in the tumorigenesis have opened new views toward the 
development of molecular targeting and tumor prevention 
associated with the Hh pathway. Special attention has been 
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paid to the targeted Hh signaling pathway inhibition (HPI) as 
a treatment for locally aggressive BCCs and metastatic BCCs, 
when radiotherapy and surgery are not effective treatment 
modalities. Therefore, HPI therapy approach is a new hope for 
patients with difficult-to-treat BCCs.
More than 50 HPI molecules have been identified, which 
act at different levels of the Hh signaling pathway. HPIs are 
categorized as Hh ligand inhibitors, Smo antagonists, Gli 
inhibitors, inhibitors of bromodomain and extra-terminal 
domain (BET) family of proteins, atypical protein kinase C 
(aPKC) inhibitors, and phosphodiesterase inhibitors (Table 2).
Hh ligand inhibitors act at the highest level of the signaling 
pathway by inhibiting the binding of Hh protein to Ptch recep-
tor [145]. On the other hand, Smo antagonists bind to the Smo 
drug-binding pocket, thus preventing the downstream acti-
vation of the Hh signaling cascade [146]. Smo inhibitors cur-
rently used in clinical trials are IPI-926 (saridegib), BMS833923 
(XL-139), PF04449913 (glasdegib), LY2940680 (taladegib), 
LEQ506, and TAK-441, whereas GDC-0449 (vismodegib) and 
LDE225 (sonidegib) have been approved by the US Food and 
Drug Administration, but are not in use yet [22,147,148].
Due to its pharmacokinetic properties, sonidegib is a highly 
effective drug [149]. In addition to treating BCC, there is a signif-
icant interest in the use of sonidegib in the treatment of MB and 
renal, lung, pancreatic, and ovarian carcinomas, along with hema-
tologic malignancies, such as myeloid leukemia and lymphoma.
Vismodegib has a similar safety profile as sonidegib, but 
a Phase II clinical trial with vismodegib revealed its lower 
therapeutic efficacy and more serious side effects, such as sig-
nificant fatigue, hyponatremia, hypocalcemia, muscle spasms, 
and atrial fibrillation [150].
Although Smo inhibitors possess a great potential for the 
treatment of BCC, mutations in drug-binding pocket may 
result in the resistance of tumor cells to these drugs. Therefore, 
the main focus is on the antagonists of Smo receptors that do 
not bind to the same binding site as sonidegib and vismodegib, 
such as itraconazole [151] and on the common antagonists of 
Hh signaling pathway, such as Gli-transcription factor inhibi-
tors HPI-1, HPI-2, GANT-56, GANT-61, and arsenic trioxide.
The viability and proliferation of tumor cells due to aber-
rant Hh signaling activity in Smo-resistant tumors can also 
be decreased by BET inhibitors. JQ1 is, among others, a BET 
inhibitor commonly used in research studies. It was shown 
that BET inhibitors also inhibit the growth of MB and BCC 
and increase the survival in mouse models [152].
Phosphodiesterase inhibitors were useful in the treatment 
of Smo-resistant MB in vivo [153] and aPKC inhibitors could be 
useful in the treatment of resistant BCCs [154]. Several natural 
molecules have also shown some benefits in cancer treatment. 
For example, deguelin is a flavonoid with anticarcinogenic 
and antiproliferative activities. It induces apoptosis and cell 
cycle arrest and inhibits blood vessel formation [155]. Many 
studies refer to deguelin as the regulator of the Hh signaling 
pathway, and several studies have already shown its excellent 
potential in the treatment of various malignant tumors such as 
gastric, lung and breast cancers, and more recently, pancreatic 
cancer [155].
Furthermore, it has been found that Siegesbeckia gla-
brescens sesquiterpenes suppress Gli-mediated transcriptional 
activity and proliferation of human pancreatic cells [156]. Also, 
recent studies indicate that Smo protein can be repressed by 
the secretion of Ptch-dependent (pro-)Vitamin D3 [65].
CONCLUSIONS AND FUTURE 
DIRECTIONS
Novel findings reveal multiple roles of the Hh signaling 
pathway in the development and progression of various can-
cers. Although the link between the Hh signaling pathway 
and tumorigenesis is very heterogeneous, it is known that 
the aberrant activation of Hh signaling leads to the growth, 
proliferation, and invasion of tumor cells. Therefore, further 
research and understanding of the specific role of deregu-
lated activation of Hh signaling in different cancer types will 
hopefully contribute to the development of novel anti-can-
cer treatment modalities. Smo inhibitors represent a new 
and promising treatment option with possible benefits for 
some cancers. Their entry into clinical use provides a new 
avenue and hope for many patients with advanced and 
TABLE 2. Targeted tumor therapy associated with Hh signaling 
pathway
Group Drug
Hh ligand inhibitors Neutralizing antibodies (5E1), robotnikinin
Smo antagonists
Cyclopamine
Saridegib
Vismodegib
Sonidegib
Glasdegib
Taladegib
LEQ506
TAK- 441
XL-139
Itraconazole
Gli inhibitors
HPI-1
HPI-2
GANT-56
GANT-61
ATO
BET inhibitors JQ1
aPKC inhibitors PSI
Phosphodiesterase 
inhibitors
NVP-ABE171
cilomilast
Natural products
Deguelin
Siegesbeckia glabrescens extracts
Vitamin D3
Hh - Hedgehog; Ptch - Patched; Smo - Smoothened; Gli - glioma-associ-
ated oncogene; BET - bromodomain and extra-terminal domain family of 
proteins; aPKC- atypical protein kinase C
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chemorefractory BCCs. Their use in the treatment of other 
cancer types, such as pancreatic cancer or MB, has also been 
proposed. However, due to harmful and potentially toxic 
side-effects of Smo inhibitors, undetermined safety in chil-
dren, and the evidence that some patients develop resistance 
to Smo-inhibitors, efforts are being made to develop new 
classes of drugs. CSCs seem to be critical for tumorigenesis 
and HPI resistance in various tumors, so the combination 
of systemic HPI with other cytotoxic inhibitors is required. 
Further research studies should elucidate other mechanisms 
of Hh actions and translate their findings into novel, better, 
and safer anti-cancer therapies.
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